Michael B. Jordan, MD

Lipopolysaccharide-responsive and beige-like anchor protein (LRBA) functional deficiency caused by biallelic LRBA missense variants characterized by Evans syndrome or colitis. Chiang, SC C; Yang, L; Owsley, E; Husami, A; Akeno, N; Cobb, C; Hartog, NL; Elizalde, A; Seroogy, CM; Blanchard-Rohner, G; Marsh, R; Bleesing, J; Jordan, MB; Marwaha, AK. Journal of Allergy and Clinical Immunology. 2025; 156:270-278.

Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary. Chandrakasan, S; Allen, CE; Bhatla, D; Carter, J; Chien, M; Cooper, R; Draper, L; Eckstein, OS; Hanna, R; Hays, JA; Walkovich, KJ; Yee, JD; Zoref-Lorenz, A; Behrens, EM. Immunotherapy. 2025; 17:461-478.

Recognizing and Managing Secondary Hemophagocytic Lymphohistiocytosis in Adults: A Practical Clinical Guide. Zoref-Lorenz, A; Rocco, J; Schwartz, DM; Jordan, M. Hematology/Oncology Clinics of North America. 2025; 39:577-596.

The optimized HLH inflammatory index: A novel prognostic tool for newly diagnosed patients with diffuse large B-cell lymphoma—Discovery and validation. Zoref Lorenz, A; Cahn, E; Mou, E; Wang, Y; Maurer, MJ; Feldman, AL; Negaard, BJ; Mwangi, R; Itchaki, G; Nowakowski, GS; Goyal, G; Witzig, TE; Cerhan, JR; Jordan, M. Journal of Clinical Oncology. 2025; 43:7073.

122 | IDENTIFYING HARMFUL HYPERINFLAMMATION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING THE OHI (OPTIMIZED HLH INFLAMMATORY) INDEX—DISCOVERY AND VALIDATION IN REAL‐WORLD PATIENTS. Zoref‐Lorenz, A; Cahn, EJ; Mou, E; Cholack, G; Wang, Y; Maurer, M; Feldman, AL; Negaard, BJ; Mwangi, R; Itchaki, G; Novak, AJ; Witzig, TE; Cerhan, JR; Jordan, M. Hematological Oncology. 2025; 43.

PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis. Brown-Burke, F; Saadey, R; Mao, HY C; Marra, P; Brooks, E; Wandtke, A; Hout, I; Leon, S; Sharma, A; Yasin, A; Chen, CJ; Jordan, MB; Baiocchi, RA; Shindiapina, P. Blood Advances. 2025; 9:2379-2392.

T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis. Wozny, N; Niebur, H; Jordan, M. 2025; 1.

Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis. Jess, J; Verkamp, B; Jordan, M. 2025; 1.

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. 2025; 1.

Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity. Khoury, R; Jordan, M; Bleesing, J; Kumar, A; Saldana, BD; Verkamp, B; Davies, S; Marsh, R; Chandra, S. 2025; 1.